Articles tagged with Thrombosis
A study found 5 genetic variations associated with the risk of nonfatal venous thrombosis in postmenopausal women, highlighting potential new targets for prevention and treatment. The findings suggest that genetic factors may play a significant role in the development of this condition.
The Society for Cardiovascular Angiography and Interventions (SCAI) released a clinical alert on the risks of late thrombosis associated with drug-eluting stents. The alert provides practical advice for physicians to minimize this risk, including careful patient selection and use of dual anti-clotting medications.
The Society for Cardiovascular Angiography and Interventions president urges the FDA to consider the benefits of drug-eluting stents when evaluating risks. The use of these devices has been linked to a slightly higher risk of late blood clot formation, but the benefits of preventing restenosis outweigh the risks.
Researchers found that patients with uncontrolled high blood sugar before surgery are 6.2 times more likely to develop pulmonary embolism, a life-threatening condition. Tightening glucose control can reduce this risk and hospital stays.
A large study found that traveling for more than 4 hours increases the risk of venous thrombosis by 2-fold. High-risk groups, including those with factor V Leiden and oral contraceptives, have a significantly increased risk of thrombosis after air travel.
A recent study has found that thrombotic complications occur in 5.2% of children with leukaemia, with the highest risk during antileukaemic therapy induction phase. The researchers have identified several factors associated with an increased risk of thrombosis and explored the role of genetic determinants.
A randomized trial involving 250 patients with advanced prostate cancer found that high-dose calcitriol (DN-101) significantly reduced venous and arterial thromboses compared to a placebo. This unexpected benefit offers an avenue of investigation for improved safety in various cancers.
A new study conducted by researchers at the University of Leicester found no evidence that low air pressure and low oxygen levels during long-haul flights increase the risk of blood clots. The study, which included 73 healthy volunteers, assessed the effects of hypobaric and hypoxia on markers of blood clotting.
A study analyzing data from the Women's Health Initiative found that postmenopausal hormone therapy may increase the risk of developing venous thromboembolism, particularly in women with higher physical activity levels and lower HDL cholesterol. The risk was significantly increased for deep vein thrombosis, but not for pulmonary embolism.
A large-scale study in the UK found that both respiratory and urinary tract infections increase the risk of deep vein thrombosis. The risk is particularly high in the first two weeks after infection. Researchers suggest a causal relation between infections and venous thromboembolism.
Researchers found increased clotting marker concentrations during flights compared to sitting and daily activities, suggesting additional mechanisms underlying air travel-related thrombosis. The study included 71 healthy volunteers with varying risk factors for thrombosis, including genetic mutations and oral contraceptives.
A new clinical prediction rule for estimating the probability of PE significantly reduces adverse outcomes by identifying patients at low or high risk. The revised Geneva score provides a standardized, easy-to-compute tool for diagnosing and managing PE.
Researchers found that certain carbon nanoparticles activate human platelets and stimulate blood clotting, leading to increased risk of cardiovascular disease. The study also revealed that some nanoparticles mimic molecular bridges involved in platelet interactions.
This study reveals that airborne particulate matter is associated with an increased risk of heart attack, particularly in individuals with damaged arteries. The research suggests that exposure to these pollutants can lead to lung inflammation and fatal blood clots.
Researchers have discovered a promising new treatment option for haemophilia and heart disease by targeting the P-selectin protein. Infusion of P-selectin could provide an affordable and effective means of achieving clotting to stop bleeding incidents in haemophiliacs.
Research shows that cocoa's flavinoids can inhibit platelet function, potentially preventing coronary heart disease. In contrast, people with non-O blood types are at increased risk of deep vein thrombosis (DVT), particularly those carrying the Factor V Leiden variant protein.
Researchers found that wearing knee-length graduated compression stockings reduced DVT risk by 95%, with only two participants developing the condition out of nearly 2,500. The review also highlights the importance of regular exercise and hydration to counteract the risks of long-haul flights.
An observational study found that drug-releasing stents have a higher incidence of stent thrombosis beyond 30 days compared to clinical trials. The study identified premature antiplatelet therapy discontinuation, kidney failure, and diabetes as independent predictors of stent thrombosis.
Researchers discovered that low levels of protein Z and S early in pregnancy can increase the risk of pregnancy complications. The study included 103 women with normal pregnancies, 106 with pregnancy complications, and 20 with inherited clotting conditions. Women with prior complications may be at higher risk for future issues.
A new study published in the Journal of Clinical Investigation suggests that low-dose aspirin therapy may be a viable treatment option for pre-eclampsia during pregnancy. The research team created a mouse model that mimics low-dose aspirin therapy and found no significant complications, paving the way for further treatment options.
Patients with cancer have a significantly increased risk of developing venous thrombosis, with the risk highest in the first few months after diagnosis. The study found that patients with hematological, lung, or gastrointestinal cancers had a higher risk compared to those without cancer.
Substances in wine have been shown to share the characteristics of ethanol, preventing blood clotting and providing cardio-protective effects. Additionally, wine has been found to reduce mortality from cancer compared to other alcoholic beverages, thanks to its antioxidant properties.
A study published in the Journal of Thrombosis and Haemostasis found that moderate amounts of alcohol can reduce cardiovascular risk in women, particularly those who are postmenopausal. The research suggests that low to moderate wine consumption may have a favorable effect on cardiovascular events in this demographic.
A meta-analysis of 156 studies found that heavy alcohol drinking is strongly associated with an increased risk of primary liver cancer, breast cancer, large bowel cancer, and other related diseases. The risks are shown to increase with the amount of alcohol consumed, but no threshold below which no effect is evident.
The Leducq International Network Against Thrombosis aims to encourage idea exchange between institutions researching thrombosis in vascular disease. The five-year grant will support faculty and students exchanging research time and technology.
Researchers found that statins decrease abnormalities associated with antiphospholipid antibodies, which can cause recurring blood clots. Statins may provide an alternative therapy to warfarin for patients with aPL.
A recent study reports four cases of angiographically-confirmed stent thrombosis after elective implantation of drug-eluting stents, resulting in myocardial infarction. The authors emphasize the need for careful long-term follow-up to assess late thrombosis risk
A recent study published in JAMA found that the use of estrogen plus progestin therapy was associated with an increased risk of venous thrombosis. The risk was higher among older and overweight postmenopausal women, as well as those with a genetic mutation for Factor V Leiden.
A new study found that wearing below-the-knee elastic compression stockings every day reduces the incidence of DVT complications from 49% to 26% and severe complications from 12% to 3.5% after a blood clot in two years. The study suggests that stocking therapy should be routine after a deep-vein blood clot.
A study of long-haul air travelers found a 1% risk of venous thromboembolism (VTE), including pulmonary embolism and deep vein thrombosis. Traditional risk factors and prophylactic measures may need further investigation to reduce the risk.
Researchers found no significant effect of inhaled corticosteroid use on COPD mortality, hospitalizations, or exacerbations. An ultrasound-based screening strategy for critically ill patients with femoral catheters could add to quality-adjusted life expectancy and prevent pulmonary embolism.
A new direct thrombin inhibitor, ximelagatran, has shown promising results in preventing recurrent venous thromboembolism in patients with acute deep vein thrombosis. The study found that oral ximelagatran was as effective as enoxaparin/warfarin in preventing this condition, while also reducing major bleeding and mortality rates.
A clinical trial found that aspirin treatment significantly reduced the risk of thrombosis, cardiovascular death, and minor bleeding events in patients with polycythemia vera. The study suggests that aspirin can be a safe and effective treatment option for these patients.
Researchers discovered a two-fold increased risk of deep vein thrombosis and pulmonary embolism with estrogen plus progestin use. Age and obesity were primary determinants of increased absolute risk, while genetic variants such as Factor V Leiden also contributed to thrombosis risk.
The American College of Chest Physicians has established a new Distinguished Scholar program, supporting the development of an original educational project on thrombosis and patient care. Dr. Morris will explore pulmonary care in his project, creating new knowledge to advance best practices.
Researchers have developed a new drug, ximelagatran, that is absorbed quickly and has no food or drug interactions, making it easier to manage than warfarin. The study found that the new drug was significantly superior to warfarin in preventing blood clots, with fewer side effects.
A multicentre hospital-based case-control study found that transdermal estrogen replacement therapy is not associated with an increased risk of venous blood clots in postmenopausal women. In contrast, oral estrogen replacement therapy was linked to a significantly higher risk of developing venous thromboembolism.
Researchers exposed eight healthy participants to hypoxia and normal air conditions to investigate potential link between air travel and venous thrombosis (DVT). The study found no significant changes in clotting activity during hypoxic exposure, but a larger study is required to confirm these findings.
The Prevention of Recurrent Venous Thromboembolism trial found that low-dose warfarin prevents episodes of deep vein thrombosis and pulmonary embolism with a significant reduction in risk. The study showed no major bleeding complications, making it an effective and safe treatment option.
Results from THRIVE III study demonstrate that oral EXANTA is effective in preventing recurrence of VTE events by 84% compared to placebo. The data also show no significant increase in total bleeding events for EXANTA.
A team-based approach to care significantly reduces hospital stays and the risk of blood clots in patients with stroke. The study, published in the Canadian Medical Association Journal, found a $2.1 million annual savings per 1000 patients treated.
The NWO/Spinoza Award is presented to four Dutch scientists for their groundbreaking research in mathematics, computer science, and medicine. Professor Henk Barendregt and Els Goulmy receive awards for their work on lambda calculus and minor histocompatibility antigens, respectively.
A study published in Neurology found a link between blood doping and cerebral blood clots in cyclists. The combination of erythropoietin, growth hormone, and high-dose vitamin A use likely contributed to the condition.
Deep-vein thrombosis (DVT) is a serious medical condition with minimal symptoms, yet it has never received the same attention as heart attack or stroke. The Council for Leadership On Thrombosis Awareness and Management aims to raise awareness and educate the public about DVT risk factors and symptoms.
A new study finds that the updated birth control pills pose a significant stroke risk for women. The risk is similar to that of first-generation pills and higher than non-users.
A prospective study found that women with Factor V Leiden mutations had low live birth rates compared to those without the mutation. The research suggests that targeted anti-blood clotting treatment may be beneficial for these women, and screening is recommended.
A survey of intensive care units found that many strategies to prevent deep vein thrombosis (DVT) were not being used, including support stockings and low molecular weight heparin. Physicians need more education on latest techniques to reduce DVT incidence, and fundamental research is needed to understand the condition.
A new study has found that the rate of clots forming inside stents is three times higher than generally appreciated, with a 3.5% risk for patients with acute coronary syndromes. This finding may prompt cardiologists to rethink their approach to stent placement and consider alternative treatments to lower this risk.
Research on designer mice lacking vascular thrombomodulin has led to a greater understanding of the protein's importance in preventing blood clots. The study reveals that this critical regulator is necessary for maintaining normal blood coagulation, with severe consequences for those lacking it.
A study found that extended-duration prophylaxis significantly reduced the incidence of symptomatic VTE in patients undergoing total hip or knee replacement. The reduction in risk is equivalent to about 20 symptomatic events per 1000 patients treated.
Researchers at Duke University Medical Center found that artificially intensifying the heart's pumping action, known as aortic counterpulsation, showed modest but significant benefits for the sickest heart attack patients. The technique, combined with clot-busting drugs, reduced six-month mortality rates by 4% compared to treatment alone.
Vascugel, a perivascular tissue engineered implant, prevents intimal hyperplasia by regulating biochemical compounds involved in blood vessel repair. The study supports the potential use of Vascugel to enhance cardiovascular procedures and reduce costs associated with (re)stenosis.
The METHRO II study found that H 376/95 was effective in preventing venous thrombo-embolism in patients undergoing total hip or total knee replacement surgery. The incidence of venous thrombo-embolism was significantly lower with the highest dosage of H 376/95 compared to dalteparin.
Researchers develop a mouse model for intrauterine growth retardation and find that administering indomethacin during pregnancy can rescue underweight fetuses. The study provides promising insights into the underlying biochemistry of IUGR and identifies a potential therapeutic approach.
Scientists at Vanderbilt University Medical Center have identified a new target for drugs that inhibit tumor angiogenesis. Thromboxane A2 receptor antagonists show promise in blocking endothelial cell migration and preventing blood vessel formation associated with tumors.
A study by researchers at UCSF Medical Center found that the electrocardiogram is highly inaccurate for patients with left bundle-branch block (LBBB), leading to under-treatment. This affects approximately 100,000 Americans with LBBB who experience myocardial infarction every year.
A new study found that clot-busting drugs can save legs as effectively as invasive surgery, reducing the need for open surgical procedures by over 30%. The experimental drug, recombinant urokinase, showed no significant difference in death or amputation rates between surgical and non-surgical patients.
Researchers at Johns Hopkins Medicine have identified a unique molecular defect responsible for polycythemia vera, a blood disorder that can be difficult to diagnose. The finding may lead to the development of a definitive test for the condition, which could potentially increase patient lifespan.
Researchers found that a vitamin supplement with folic acid, B-6, and B-12 reduced homocysteine levels and improved biochemical markers in the blood of 27 patients who had suffered a stroke. The study suggests that lowering homocysteine may have multiple biological effects on endothelial cells.
Researchers found that low-frequency ultrasound enhances the effectiveness of thrombolytic drugs in dissolving blood clots deep within the brain. This combination therapy may reduce the duration and doses of medication needed, minimizing risks of bleeding and other complications associated with stroke treatment.